News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Crucell Announces Large Human Clinical Trial With Avian Influenza Vaccine


5/31/2006 1:18:58 PM

Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: SW CRX) today announced the commencement of a large randomized, observer-blind and dose-ranging study to test a vaccine against avian influenza virus in humans. The trial, performed in collaboration with a team based in Leicester, UK, will oversee the vaccination of 560 healthy adult individuals.

Read at BioSpace.com

comments powered by Disqus
   
Bird Flu

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES